LOS ANGELES--(BUSINESS WIRE)--Hythiam, Inc. (NASDAQ:HYTM) announced that the initial results of a double-blind, placebo-controlled study utilizing Hythiam’s PROMETA® Treatment Program (PROMETA) were presented at the Research Society on Alcoholism (RSA) conference in Washington, DC, by leading alcoholism expert and RSA President, Raymond Anton, M.D., of Medical University of South Carolina. At the time of the RSA presentation, the data presented covered the initial 6-week active treatment phase of the 14-week study. The study was designed to evaluate the impact of PROMETA on percent days abstinent, other use measures and cravings. Alcoholic subjects were stratified into 2 groups upon enrollment: those with higher alcohol withdrawal, as defined by their Clinical Institute Withdrawal Assessment (CIWA) scores, and those with lower CIWA scores. Subjects were not required to maintain prior abstinence. The key study findings are:
